When Filipinos take medicine, they place their trust not only in the science but in the Food and Drug Administration (FDA), the institution responsible for ensuring that every product reaching the public is safe, effective, and of reliable quality.
This responsibility extends far beyond listing side effects on a label. Medicine safety is a continuous commitment that spans the entire life cycle of a product, from its earliest testing to its final use by patients.
Protecting patients revolves around threats they rarely see. Counterfeit medicines, especially those sold through informal or online channels, may look legitimate but have no therapeutic value. But how about medicines that do carry brand names? Medicines that come from legitimate sources, mostly from abroad, but become are substandard because of the way these were manufactured, shipped, stored or delivered?
Clearly, the FDA’s mandate begins long before a medicine appears on a pharmacy shelf. In laboratories and clinical trials, researchers test not only whether a drug works but whether its risks are acceptable. Regulators scrutinize this evidence before granting approval, weighing benefits against potential harm.
Approval is only the beginning. Once a medicine enters the market, real world use can reveal issues that clinical trials were too small or too controlled to detect. Safety, therefore, is not a single decision but an ongoing process of monitoring and reassessment.
And how about unregistered products, which may also be sold in legitimate channels like the mom-and-pop drugstore? How is the public to know the quality, safety and effectiveness of these medicines? With slow logistics and improper storage medicines also spoil and lose potency. If exposed to heat or humidity, a particular concern in the Philippines’ tropical climate, the active ingredients may degrade. These risks show that medicine safety is as much about vigilance as it is about chemistry.
This vigilance is anchored in pharmacovigilance, the system for detecting and analyzing adverse events once medicines are in use. By encouraging healthcare professionals and patients to report unexpected reactions, regulators can identify early warning signs and act before problems escalate. Participation in global safety networks strengthens this effort, allowing the Philippines to share data and anticipate risks emerging in other countries.
New challenges continue to emerge, especially with the rise of online medicine sales. Digital platforms broaden access but also create openings for counterfeit, unregistered and substandard products to reach consumers. Stronger surveillance, combined with public education, is essential to help Filipinos distinguish trusted sources from doubtful ones. In this environment, the FDA’s role is not only regulatory but confidence building — assuring the public that the medicines they rely on are worthy of their trust.
Patient safety is ultimately about more than managing side effects. This will be the very discussion of The Manila Times (TMT) Health Forum 2026 called “Regulating trust: Ensuring quality, safety, and effectiveness in medicines.”
To be held on July 7, 2026, 1 to 5 pm, at Holiday Inn Manila, it is about protecting people from hidden dangers in the delivery of medicines, ensuring that these remain safe throughout their use, and upholding a healthcare system where trust is inseparable from treatment. The forum will feature speakers from the FDA, Department of Health, the industry and academe. Fireside discussions will be moderated by Ben Kritz, TMT columnist.
